216 related articles for article (PubMed ID: 18369325)
1. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
Power AT; Bell JC
Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
[TBL] [Abstract][Full Text] [Related]
2. Potential of tumour cells for delivering oncolytic viruses.
Raykov Z; Rommelaere J
Gene Ther; 2008 May; 15(10):704-10. PubMed ID: 18356816
[TBL] [Abstract][Full Text] [Related]
3. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
Munguia A; Ota T; Miest T; Russell SJ
Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
[TBL] [Abstract][Full Text] [Related]
4. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the "Trojan horse" approach.
Deng W; Jia J
Med Hypotheses; 2008; 70(4):842-4. PubMed ID: 17869010
[TBL] [Abstract][Full Text] [Related]
5. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
Thorne SH; Contag CH
Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
[TBL] [Abstract][Full Text] [Related]
7. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?
Stanford MM; Breitbach CJ; Bell JC; McFadden G
Curr Opin Mol Ther; 2008 Feb; 10(1):32-7. PubMed ID: 18228179
[TBL] [Abstract][Full Text] [Related]
8. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated cancer gene therapy and virotherapy (Review).
Fukazawa T; Matsuoka J; Yamatsuji T; Maeda Y; Durbin ML; Naomoto Y
Int J Mol Med; 2010 Jan; 25(1):3-10. PubMed ID: 19956895
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
11. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
12. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
Bauzon M; Hermiston TW
Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
[TBL] [Abstract][Full Text] [Related]
13. ReVOLT: radiation-enhanced viral oncolytic therapy.
Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
[TBL] [Abstract][Full Text] [Related]
14. Directing systemic oncolytic viral delivery to tumors via carrier cells.
Nakashima H; Kaur B; Chiocca EA
Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy progress and prospects cancer: oncolytic viruses.
Liu TC; Kirn D
Gene Ther; 2008 Jun; 15(12):877-84. PubMed ID: 18418413
[TBL] [Abstract][Full Text] [Related]
16. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
17. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
19. [Measles virus: a future therapeutic agent in oncology?].
Touchefeu Y; Schick U; Harrington KJ
Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
